RichardSamuelFinnMD
Oncology • Santa Monica, CAAssistant Professor, Medicine, UCLA School of Medicine
Are you Dr. Finn?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 95 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
2020 Santa Monica Blvd
Ste 600
Santa Monica, CA 90404Phone+1 310-829-5471Fax+1 310-829-6192
Summary
- Dr. Richard Finn, MD is an oncologist in Santa Monica, California. He is currently licensed to practice medicine in California. He is affiliated with UCLA Medical Center-Santa Monica and is an Assistant Professor at UCLA School of Medicine.
Education & Training
UCLA David Geffen School of Medicine/UCLA Medical CenterFellowship, Hematology and Medical Oncology, 2000 - 2003- UCLA David Geffen School of Medicine/UCLA Medical CenterResidency, Internal Medicine, 1997 - 2000
Keck School of Medicine of the University of Southern CaliforniaClass of 1997
Certifications & Licensure
CA State Medical License 1999 - 2026- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Immunization With AFP + GM CSF Plasmid Prime and AFP Adenoviral Vector Boost in Patients With Hepatocellular Carcinoma Start of enrollment: 2009 Jun 01
- Study of Panobinostat Monotherapy in Women With v-ERB-B2 Avian Erythroblastic Leukemia Viral Oncogene Homolog 2 (HER2) Positive Locally Recurrent or Metastatic Breast Cancer Start of enrollment: 2009 Feb 01
- Dasatinib and Gemcitabine Hydrochloride or Gemcitabine Hydrochloride Alone in Treating Patients With Pancreatic Cancer Previously Treated With Surgery Start of enrollment: 2011 Jan 13
- Join now to see all
Publications & Presentations
PubMed
- 68 citationsMolecular Markers of Response to Anti-PD1 Therapy in Advanced Hepatocellular Carcinoma.Philipp K Haber, Florian Castet, Miguel Torres-Martin, Carmen Andreu-Oller, Marc Puigvehí
Gastroenterology. 2023-01-01 - 250 citationsAssociation of inflammatory biomarkers with clinical outcomes in nivolumab-treated patients with advanced hepatocellular carcinomaBruno Sangro, Ignacio Melero, Samir Wadhawan, Richard S. Finn, Ghassan K. Abou-Alfa
Journal of Hepatology. 2020-07-22 - 2733 citationsAASLD guidelines for the treatment of hepatocellular carcinomaJulie K. Heimbach, Laura Kulik, Richard S. Finn, Claude B. Sirlin, Michael Abecassis
Hepatology. 2018-01-01
Authored Content
- Atezolizumab plus Bevacizumab in Unresectable Hepatocellular CarcinomaMay 2020
- Atezolizumab plus Bevacizumab in Unresectable Hepatocellular CarcinomaMay 2020
- Palbociclib plus Endocrine Therapy in Older Women with HR+/HER2– Advanced Breast Cancer: A Pooled Analysis of Randomised PALOMA Clinical StudiesAugust 2018
Press Mentions
Novartis Announces Tislelizumab Demonstrated Efficacy and Tolerability in First-Line Advanced Liver Cancer in Phase III TrialSeptember 10th, 2022- PALOMA-2: No Overall Survival Benefit Reported with Palbociclib/Letrozole in Advanced Breast CancerJuly 26th, 2022
- New Data on Emerging Treatments for Liver Cancer Raise Hope for Advanced Disease PatientsAugust 27th, 2020
- Join now to see all
